Uromitexan

Uromitexan

mesna

Manufacturer:

Transfarma Medica Indah

Marketer:

A Menarini
Concise Prescribing Info
Contents
Mesna
Indications/Uses
Prevention of urotoxic effects of oxazaphosphorines.
Dosage/Direction for Use
Antineoplastic as IV bolus: Adult Uromitexan as 20% of the antineoplastic dose on a wt for wt basis given IV at 4-hrly intervals, beginning at the same time as the antineoplastic inj at 0, 4 & 8 hr. Childn Carry out administrations more frequently (eg, 6 times) & at shorter intervals (eg, 3 hr). Antineoplastic as continuous infusion: Uromitexan as 20% of the total antineoplastic dose given by IV inj, followed by 100% of the total antineoplastic dose by IV infusion over 24 hr, then followed by up to 50% by infusion over a further 12 hr.
Special Precautions
Protective effect applies only to the urinary tract.
Adverse Reactions
GI effects, headache, malaise, skin rash. Allergic symptoms (rare). Vein irritation.
ATC Classification
V03AF01 - mesna ; Belongs to the class of detoxifying agents used in antineoplastic treatment.
Presentation/Packing
Form
Uromitexan infusion 400 mg
Packing/Price
(amp) 4 mL x 15 × 1's (Rp1,714,400/boks)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in